Digest Network Come funziona
Network
/
Società
Co
Non verificato

Coya Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

55 comunicati stampa

Guarda tutti i comunicati
08/06/2026
Industria
Scienza
Medicina - Varie
Biologia
Biotecnologia
Sanità
Salute
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Sanità
Salute
Farmaceutica
Eventi
Industria
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Psichiatria
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Industria
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/04/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Scienza
Psichiatria
Medicina - Varie
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
02/04/2026
Mercato del lavoro
Sanità
Scienza
Farmaceutica
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/03/2026
Analisi di mercato
Industria
Salute
Biotecnologia
Sanità
Scienza
Farmaceutica
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/03/2026
Psichiatria
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Mercato azionario
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/02/2026
Web e Social Network
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/01/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Finanza
Coya Therapeutics Announces $11.1 Million Private Placement
Fonte
Coya Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0